(ALHC) Alignment Healthcare - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US01625V1044
ALHC: Medicare, Advantage, Plans, Health, Care, Services
Alignment Healthcare LLC (NASDAQ: ALHC) is a tech-driven Medicare Advantage insurer that has carved out a niche serving seniors in the United States. Founded in 2013 and headquartered in Orange, California, the company has built a platform that relies heavily on data analytics and personalized care coordination to deliver tailored health plans for its members. Its consumer-centric approach focuses on addressing the diverse needs of seniors, a demographic that often requires more complex and coordinated medical care.
The companys value proposition lies in its ability to leverage technology to improve health outcomes and reduce costs. By integrating advanced analytics, Alignment Healthcare can identify high-risk patients earlier and intervene with preventive measures. This proactive approach not only enhances the quality of care but also helps in managing medical expenses, which is critical in the Medicare Advantage space where margins are thin. The companys platform also includes tools for care management, patient engagement, and network optimization, all of which contribute to a more efficient healthcare delivery model.
From a financial perspective, Alignment Healthcare operates in a growing market. The Medicare Advantage program has seen steady enrollment increases, driven by the aging U.S. population and the attractiveness of MA plans over traditional Medicare. The companys market capitalization stands at $2.658 billion, reflecting investor confidence in its growth prospects. While the stock currently trades at a price-to-sales ratio of 1.08, the companys focus on operational efficiency and expansion into new markets could drive future valuation changes. Notably, the companys price-to-book ratio of 23.21 indicates a premium valuation relative to its book value, which may be attributed to its technology-driven business model and growth trajectory.
Alignment Healthcares strategy revolves around scaling its Medicare Advantage plans while maintaining its focus on senior care. The company has demonstrated an ability to expand into new geographic markets while maintaining its core competencies in care coordination and cost management. For investors, the key will be monitoring how effectively the company can balance growth with profitability in a highly competitive and regulated industry. Its ability to innovate and adapt to changing regulatory and market conditions will be critical to its long-term success.
Web URL: https://www.alignmenthealth.com
Additional Sources for ALHC Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ALHC Stock Overview
Market Cap in USD | 2,925m |
Sector | Healthcare |
Industry | Healthcare Plans |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2021-03-26 |
ALHC Stock Ratings
Growth 5y | 2.15% |
Fundamental | -7.08% |
Dividend | 0.0% |
Rel. Strength Industry | 225 |
Analysts | 4.23/5 |
Fair Price Momentum | 17.08 USD |
Fair Price DCF | 4.00 USD |
ALHC Dividends
No Dividends PaidALHC Growth Ratios
Growth Correlation 3m | 75.5% |
Growth Correlation 12m | 95.2% |
Growth Correlation 5y | -51.3% |
CAGR 5y | -2.29% |
CAGR/Max DD 5y | -0.03 |
Sharpe Ratio 12m | 1.32 |
Alpha | 218.70 |
Beta | 0.72 |
Volatility | 61.17% |
Current Volume | 3851k |
Average Volume 20d | 2551.9k |
As of March 15, 2025, the stock is trading at USD 15.79 with a total of 3,851,034 shares traded.
Over the past week, the price has changed by +6.04%, over one month by +15.42%, over three months by +40.86% and over the past year by +227.59%.
Neither. Based on ValueRay Fundamental Analyses, Alignment Healthcare is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -7.08 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALHC as of March 2025 is 17.08. This means that ALHC is currently overvalued and has a potential downside of 8.17%.
Alignment Healthcare has received a consensus analysts rating of 4.23. Therefor, it is recommend to buy ALHC.
- Strong Buy: 8
- Buy: 1
- Hold: 3
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, ALHC Alignment Healthcare will be worth about 18.8 in March 2026. The stock is currently trading at 15.79. This means that the stock has a potential upside of +19.06%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 17.1 | 8% |
Analysts Target Price | 13.3 | -16% |
ValueRay Target Price | 18.8 | 19.1% |